MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Gastrointestinal problemsm(also see autonomic dysfunction)"

  • MDS Virtual Congress 2021

    Celiac disease-related antibodies in Parkinson’s Disease patients: a case control study.

    GUL. şahbaz, BOB. Barut, SDT. Tekol (Istanbul, Turkey)

    Objective: To compare anti-transglutaminase and antigliadin antibodies between Parkinson’s disease patients and healthy controls. A detailed gastrointestinal symptom investigation was studied and compared between patient…
  • MDS Virtual Congress 2021

    Fecal Calprotectin in Parkinson’s Disease and Multiple System Atrophy

    JW. Hor, ES. Khor, KK. Chong, SL. Song, CW. Chong, SY. Lim, AH. Tan (Kuala Lumpur, Malaysia)

    Objective: To investigate the levels of fecal calprotectin (a marker of intestinal inflammation), in patients with Parkinson's Disease (PD) and multiple system atrophy (MSA) compared…
  • MDS Virtual Congress 2021

    GASTROINTESTINAL SYMPTOMS ARE ASSOCIATED WITH LEFT PREDOMINANT DOPAMINE TRANSPORTER BINDING DEFICIT IN PARKINSON´S DISEASE

    K. Murtomäki, T. Mertsalmi, E. Jaakkola, E. Mäkinen, R. Levo, T. Nojonen, M. Eklund, S. Nuuttila, K. Lindholm, E. Pekkonen, J. Joutsa, T. Noponen, T. Ihalainen, V. Kaasinen, F. Scheperjans (Helsinki, Finland)

    Objective: To assess correlations between functional gastrointestinal (GI) symptoms and nigrostriatal dopamine transporter imaging asymmetry in Parkinson´s disease (PD) patients. Based on a theory that…
  • MDS Virtual Congress 2021

    Functional Constipation in Parkinson’s Disease

    S. Pavan, M. Ballal, A. Prabhu, S. Gorthi, B. Das, A. Mutreja, T. Ramamurthy, A. Pai (Manipal, India)

    Objective: To analyze and compare the Rome IV Criteria of Functional Constipation between PD and HC, with that followed by MDS-NMS, intended for determining clinical…
  • MDS Virtual Congress 2021

    A53T-SNCA-BAC transgenic mouse exhibits multiple prodromal symptoms of Parkinson’s disease: Gastrointestinal dysfunction, hyposmia and RBD-like behavior.

    T. Taguchi, M. Ikuno, H. Yamakado, R. Takahashi (Kyoto, Japan)

    Objective: To develop biomarkers and disease-modifying therapies for Parkinson’s disease, an animal model that recapitulates the early phase of the disease is indispensable. The aim…
  • MDS Virtual Congress 2021

    Evidence of gut dysbiosis in treatment-naïve de novo Parkinson’s disease

    J. Boertien, K. Murtomäki, P. Pereira, S. Vander Zee, A. Slomp, T. Mertsalmi, R. Levo, T. Nojonen, P. Laine, L. Paulin, P. Auvinen, V. Kaasinen, F. Scheperjans, T. van Laar (Groningen, Netherlands)

    Objective: To determine the gut microbiome composition of treatment-naïve de novo Parkinson’s disease (PD) patients. Background: Over fifteen studies have independently demonstrated gut dysbiosis in…
  • MDS Virtual Congress 2021

    The Gastrointestinal Dysfunction Scale – Parkinson’s Disease (GIDS-PD): a new tool to assess gastrointestinal dysfunction in Parkinson’s Disease

    M. Camacho, J. Greenland, C. Williams-Gray (Cambridge, United Kingdom)

    Objective: Objective: To develop and validate the Gastrointestinal Dysfunction Scale – Parkinson’s Disease (GIDS-PD), a self-report scale designed to assess presence and severity of Gastrointestinal…
  • MDS Virtual Congress 2020

    Effect of Lactobacillus casei supplementation on clinical response, gut microbiota and faecal metabolites in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial

    X.D Yang, X.Q He, S.Q Xu, VV. Qian, Y. Zhang, YY. Song, Q. Xiao (Shanghai, China)

    Objective: To evaluate the effect of Lactobacillus casei strain Shirota (LcS) supplementation on symptoms, gut microbiota and faecal metabolites in patients with Parkinson's disease (PD).…
  • MDS Virtual Congress 2020

    Microbiome from Parkinson’s patients shows an increase in polyamines metabolism and differentially expresses microbial bacterial taxa compared to aged-matched normal controls

    S. Melgar, N. Danso, C. Pena, J. Ahmed, S. Kumar, R. Kumar, C. Carlin, D. Linseman, D. Paredes (Denver, CO, USA)

    Objective: The goal of this study was to determine whether the microbiome from Parkinson’s disease (PD) has alterations in a) Polyamine metabolism and b) Expressed…
  • MDS Virtual Congress 2020

    The Gut Dysmotility Questionnaire (GDQ) for Parkinson’s disease: current development

    V. Räder, K.R Chaudhuri, L. Batzu, V. Leta, H. Reichmann, B. Falkenburger, L. Klingelhoefer (Dresden, Germany)

    Objective: To develop a questionnaire to screen for and monitor gastrointestinal symptoms in patients with Parkinson’s disease (PD), entitled Gut Dysmotility Questionnaire (GDQ). Background: Gut…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Screening and Treatment of Depression in Parkinson’s Disease within Movement Disorders Centers: A Quality Improvement Initiative
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley